GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
JAZZ PHARMA INC (JAZZ) [hlAlert]

Rating:
Outperform
JAZZ
up 289.61 %

JAZZ PHARMA INC (JAZZ) rated Outperform with price target $66 by Oppenheimer

Posted on: Wednesday,  May 23, 2012  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform JAZZ PHARMA INC (NASDAQ: JAZZ) on 05/23/2012, when the stock price was $43.83. Since
then, JAZZ PHARMA INC has gained 289.62% as of 11/25/2015's recent price of $170.77.
If you would have followed this Oppenheimer's recommendation on JAZZ, you would have gained 289.61% of your investment in 1281 days.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/23/2012 8:25 AM Buy
None
43.83 66.00
as of 12/31/2012
1 Week up  0.98 %
1 Month down  -1.16 %
3 Months down  -6.57 %
1 YTD up  21.49 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy